申请人:Treventis Corporation
公开号:US20170174641A1
公开(公告)日:2017-06-22
In general, among other things, compounds of Formula I are provided:
in which R
11
is e.g., 4-(pyrrolidin-1-yl)piperidin-1-yl, N-methyl-3-(pyrrolidin-1-yl)propan-1-amino, N
1
,N
1
,N
3
-trimethylpropane-1,3-diamino, N,N-dimethylpiperidin-4-amino, 3-(pyrrolidin-1-ylmethyl)azetidin-1-yl, 3-(pyrrolidin-1-ylmethanon)azetidin-1-yl, or 3-(morpholin-1-ylmethyl)azetidin-1-yl; R
13
is, e.g., phenyl optionally substituted with one or more substituents; and R
12
and R
14
are each independently hydrogen or alkyl. Methods of treatment are also provided.
一般来说,除了其他事项外,还提供了式I的化合物:其中R11例如为4-(吡咯烷-1-基)哌啶-1-基、N-甲基-3-(吡咯烷-1-基)丙-1-胺、N1,N1,N3-三甲基丙烷-1,3-二胺、N,N-二甲基哌啶-4-胺、3-(吡咯烷-1-基甲基)氮杂环丁烷-1-基、3-(吡咯烷-1-基甲酮)氮杂环丁烷-1-基或3-(吗啉-1-基甲基)氮杂环丁烷-1-基;R13例如为可选择性地被一个或多个取代基取代的苯基;而R12和R14各自独立地为氢或烷基。还提供了治疗方法。